Assessment of Serum Soluble Toll-like Receptor-4 and Interleukin-8 as Biomarkers in Patients with Breast Cancer

Ikram Khazal Al-Hasso

doi:10.54133/ajms.v6i1.568

Authors

Ikram Khazal Al-Hasso Department of Microbiology, College of Medicine, Mosul University, Nineveh, Iraq https://orcid.org/0000-0003-3580-3455

DOI:

https://doi.org/10.54133/ajms.v6i1.568

Keywords:

Biomarker, Breast cancer, Interleukin-8, Toll-like receptors

Abstract

Background: Chemokines and toll-like receptors (TLR) have a synergistic role in the initiation and progression of breast cancer. TLR-4 is involved in the invasiveness of cancerous cells. Interleukin-8 (IL-8) has a significant role in boosting the angiogenesis and growth of cancer cells. Objective: To measure the level of soluble TLR-4 and interleukin-8 in patients with breast cancer and to study the possibility of using them as diagnostic and prognostic biomarkers in these patients. Methods: The study enrolled a total of 200 female subjects: 100 patients who were diagnosed with breast cancer and 100 healthy controls. Soluble TLR-4 and IL-8 levels in the blood were evaluated by the enzyme-linked immunosorbent assay. Results: upregulated levels of soluble TLR-4 as well as interleukin-8 in individuals with breast cancer compared to controls (5.79 vs. 1.01 ng/ml for TLR-4 and 29.1 vs. 7.1 pg/ml for IL-8). The concentration of soluble Toll-like receptor-4 besides interleukin-8 is significantly higher in stage IV than in other stages. A substantial increase in these biomarkers in grade 3 was detected compared to other grades. ROC curves show that both biomarkers were useful in differentiating between healthy females and those who have breast cancer. Conclusions: High concentrations of soluble TLR-4 as well as IL-8 have been linked to advanced stages of breast cancer, and these markers were effective in detecting the disease and predicting its prognosis.

Downloads

Download data is not yet available.

References

Al-Hashimi MMY. Trends in Breast Cancer Incidence in Iraq During the Period 2000-2019. Asian Pacific J Cancer Prevent. 2021;22(12):3889-3896. doi: 10.31557/APJCP.2021.22.12.3889.

Armant MA, Fenton MJ. Toll-like receptors: a family of pattern-recognition receptors in mammals. Genome Biol. 2002;3(8):3011. doi: 10.1186/gb-2002-3-8-reviews3011.

El-Zayat SR, Sibaii H, Mannaa FA. Toll-like receptors activation, signaling, and targeting: an overview. Bull Nat Res Centre. 2019;43(1):187. PMID: 34552981.

Sameer AS, Nissar S. Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility. BioMed Res Int. 2021;2021:1157023. doi: 10.1155/2021/1157023.

Shi S, Xu C, Fang X, Zhang Y, Li H, Wen W, et al. Expression profile of Toll‑like receptors in human breast cancer. Mol Med Rep. 2020;21(2):786-794. doi: 10.3892/mmr.2019.10853.

Khadem alhosseini M, Arababadi MK. Toll-like receptor 4 and breast cancer: an updated systematic review. Breast Cancer (Tokyo, Japan). 2019;26(3):265-271. doi: 10.1007/s12282-018-00935-2.

Hao B, Chen Z, Bi B, Yu M, Yao S, Feng Y, et al. Role of TLR4 as a prognostic factor for survival in various cancers: a meta-analysis. Oncotarget. 2018;9(16):13088-13099. doi: 10.18632/oncotarget.24178.

Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, et al. Cytokines in clinical cancer immunotherapy. Br J Cancer. 2019;120(1):6-15. doi: 10.1038/s41416-018-0328-y.

Cheng D, Hao Y, Zhou W, Ma Y. Positive association between Interleukin-8 -251A > T polymorphism and susceptibility to gastric carcinogenesis: a meta-analysis. Cancer Cell Int. 2013;13(1):100. doi: 10.18632/oncotarget.18220.

Zuccari DA, Leonel C, Castro R, Gelaleti GB, Jardim BV, Moscheta MG, et al. An immunohistochemical study of interleukin-8 (IL-8) in breast cancer. Acta Histochemica. 2012;114(6):571-576. doi: 10.1016/j.acthis.2011.10.007.

Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 2001;12(4):375-91. doi: 10.1016/s1359-6101(01)00016-8

Singh JK, Simões BM, Howell SJ, Farnie G, Clarke RB. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res. 2013;15(4):210. doi: 10.1186/bcr3436.

Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, et al. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis. 2008;29(6):1148-1156. doi: 10.1093/carcin/bgn109.

Teichgraeber DC, Guirguis MS, Whitman GJ. Breast cancer staging: Updates in the AJCC cancer staging manual, 8th edition, and current challenges for radiologists, from the AJR special series on cancer staging. Am J Roentgenol. 2021;217(2):278-290. PMID: 33594908.

Edechi CA, Ikeogu N, Uzonna JE, Myal Y. Regulation of immunity in breast cancer. Cancers. 2019;11(8). doi: 10.3390/cancers11081080.

Wang X, Yu X, Wang Q, Lu Y, Chen H. Expression and clinical significance of SATB1 and TLR4 in breast cancer. Oncol Lett. 2017;14(3):3611-3615. doi: 10.3892/ol.2017.6571.

Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, et al. Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res. 2010;29(1):92. doi: 10.1186/1756-9966-29-92.

Haricharan S, Brown P. TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth. Proc Natl Acad Sci U S A. 2015;112(25):E3216-3225. doi: 10.1073/pnas.1420811112.

Chen X, Zhao F, Zhang H, Zhu Y, Wu K, Tan G. Significance of TLR4/MyD88 expression in breast cancer. Int J Clin Exp Pathol. 2015;8(6):7034-7039. PMID: 26261595.

Yang H, Wang B, Wang T, Xu L, He C, Wen H, et al. Toll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis. PloS One. 2014;9(10):e109980. doi: 10.1371/journal.pone.0109980.

Wang YC, wang ZH, Yen JH, Shen YC, Shen TC, Chang WS, et al. The contribution of interleukin-8 Rs4073 genotypes to triple negative breast cancer risk in Taiwan. Anticancer Res. 2022;42(8):3799-3806. doi: 10.21873/anticanres.15870.

Mohsin SAM, Al-Thwani AN. Clinical importance of interleukin-8 concentration in Iraqi breast cancer patients. Iraqi J Biotechnol. 2012;11(1):133-140.

Green AR, Green VL, White MC, Speirs V. Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer. 1997;72(6):937-941. doi: 10.1002/(sici)1097-0215(19970917)72:6<937::aid-ijc3>3.0.co;2-q.

Ahmed OI, Adel AM, Diab DR, Gobran NS. Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. Egypt J Immunol. 2006;13(2):61-68. PMID: 18689272.

Kitadai Y, Haruma K, Mukaida N, Ohmoto Y, Matsutani N, Yasui W, et al. Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin Cancer Res. 2000;6(7):2735-2740. PMID: 10914718.

Matsui T, Ojima A, Higashimoto Y, Taira J, Fukami K, Yamagishi I. Pigment epithelium‑derived factor inhibits caveolin‑indced interleukin‑8 gene expression and proliferation of human prostate cancer cells. Oncol Lett. 2015;10(4):2644-2648. doi: 10.3892/ol.2015.3568.

Van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol. 2002;116(1):173-177. doi: 10.1046/j.1365-2141.2002.03245.x.

Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpé S, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004;10(21):7157-7162. PMID: 15534087.

Milovanović J, Todorović-Raković N, Radulovic M. Interleukin-6 and interleukin-8 serum levels in prognosis of hormone-dependent breast cancer. Cytokine. 2019;118:93-98. PMID: 29482885.

Miller L, Kurtzman S, Wang Y, Anderson K, Lindquist R, Kreutzer D. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. Anticancer Res. 1998;18(1A):77-81. PMID: 9568059.

Tan PH, Chia SS, Toh SL, Goh JC, Nathan SS. The dominant role of IL-8 as an angiogenic driver in a three-dimensional physiological tumor construct for drug testing. Tissue Engineer Part A. 2014;20(11-12):1758-1766. doi: 10.1089/ten.TEA.2013.0245.

Fernando RI, Castillo MD, Litzinger M, Hamilton DH, Palena C. IL-8 signaling plays a critical role in the epithelial–mesenchymal transition of human carcinoma cells. Cancer Res. 2011;71(15):5296-5306. doi: 10.1158/0008-5472.can-11-0156.

Todorović-Raković N, Milovanović J. Interleukin-8 in breast cancer progression. J Interferon Cytokine Res. 2013;33(10):563-570. PMID: 23697558.

Sheikhpour R. The role of interleukin-8 and its mechanism in patients with breast cancer: Its relation with oxidative stress and estrogen receptor. Int J Cancer Manag. 2017;10(9):e8791. doi: 10.5812/ijcm.8791.